Jump to any asset
850 assets, updated daily
As of September 10, 2026, Regenxbio Inc. (RGNX) trades at $8.55. CleaRank Financial AI rates it Buy with a fair value of $19.00, 122.4% above the current price. Wall Street's consensus target is $19.00 across 11 analysts. RSI at 27 is in oversold territory, and the price is below its 50-day average of $10.86.
Regenxbio Inc. (RGNX)
Regenxbio Inc. NASDAQ
$8.55
-0.1850 (-2.12%)
Latest Price
AI Analyst Consensus
77 / 100
Regenxbio Inc. (RGNX) is currently trading at $8.73, significantly below its 50-day and 200-day moving averages ($10.86 and $10.30), indicating technical weakness. The company's recent earnings report for Q2 2026 showed a substantial EPS beat of $0.43 versus an estimate of -$0.11, a 490.91% surprise, though the stock reacted negatively with a 4.96% decline. Despite this, Wall Street sentiment remains largely positive, with a consensus rating of Buy and a median price target of $19.00, implying substantial upside potential. Revenue growth is projected to rebound, with the next quarter's sales expected to increase by 28.00% year-over-year, and next year's sales anticipated to grow by 29.00%. While the company has experienced insider selling totaling $1.5 million against $949,381 in purchases, the overall insider verdict is a moderate sell signal, which is not uncommon for companies with significant institutional holdings or parent divestitures. The oversold RSI of 26.77 suggests potential for a near-term bounce.
RGNX Price Analysis
Market Metrics
Open
$8.54
Day Range
$8.49 to $8.77
Prev Close
$8.73
Volume
15.8K
52-Week Range
$5.46 to $16.19
Market Cap
$576.30M
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, RGNX trades at 3.31x, -21% versus the sector average of 4.20x.
RGNX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, RGNX beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
RGNX Analysis
Company's Health
3/5
AI Technical Analysis
Regenxbio Inc. (RGNX) is currently trading below its key moving averages, with its price below the 50-day SMA of $10.86 and the 200-day SMA of $10.30. The Relative Strength Index (RSI) is at 26.77, indicating an oversold condition, which historically can precede a price reversal. The Moving Average Convergence Divergence (MACD) is negative at -0.45, suggesting bearish momentum, but the oversold RSI may offer a near-term support. Volume on the latest trading day was 1.41 million shares, exceeding the average volume of 1.14 million shares by 23.4%, indicating increased investor interest. Key support levels are near the current price, with the oversold RSI suggesting that further downside may be limited. The stock's proximity to its 52-week low, coupled with the oversold technicals, presents a potential entry point for investors anticipating a rebound.
ProTips
- Regenxbio Inc. (RGNX) is trading in oversold territory with an RSI of 26.77, suggesting a potential near-term bounce. Consider dollar-cost averaging into positions on any further dips.
- The median analyst target price for RGNX is $19.00, implying over 117% upside from the current price, making it an attractive speculative buy.
- Monitor insider transactions closely; while recent activity shows net selling, a shift towards net buying could signal renewed management confidence.
Key Catalysts
Bullish
Strong EPS Beat in Latest Earnings
Regenxbio Inc. reported an EPS of $0.43 versus an estimate of -$0.11 for Q2 2026, a 490.91% surprise, indicating potential operational improvements.
Source: Company Earnings ReleaseBullish
Positive Revenue Growth Projections
Analysts forecast revenue growth of 28.00% for the next quarter and 29.00% for the next year, suggesting a turnaround in sales performance.
Source: Wall Street EstimatesBullish
Oversold Technical Conditions
The RSI is at 26.77, indicating the stock is oversold and may be due for a technical rebound.
Source: Technical AnalysisBearish
Moderate Insider Selling Signal
Insiders have sold $1.5 million in stock versus purchased $949,381, indicating a moderate sell signal from management.
Source: Insider TransactionsBearish
Negative EPS and Volatile Profitability
The company currently has a negative EPS of -$3.79 and has shown inconsistent profitability in recent quarters.
Source: Fundamental AnalysisMarket Outlook
Regenxbio Inc. (RGNX) is expected to see a positive trajectory over the next 6-12 months, driven by strong revenue growth projections and a significant upside to the median analyst price target of $19.00. The company's ability to beat earnings estimates, as seen in the latest report, coupled with an oversold technical condition, suggests potential for a rebound from the current price of $8.73. The thesis could be altered by continued insider selling pressure or a failure to meet forward revenue estimates, which currently project substantial growth. However, the strong analyst conviction and the significant gap between the current price and target price present a compelling risk-reward profile for investors willing to look past short-term technical weakness and earnings volatility.
Key Statistics
| Market Cap | 576.30M |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -3.79 |
| Dividend Yield | 0.00% |
| 52 Week High | 16.19 |
| 52 Week Low | 5.46 |
Regenxbio Inc. (RGNX) exhibits a negative P/E ratio due to its negative EPS of -$3.79, making traditional valuation metrics like P/E and PEG ratios inapplicable. The company's revenue growth has been volatile, with a reported 405.7% year-over-year growth, but current quarter estimates show a -44.00% year-over-year decline. However, forward-looking estimates are more optimistic, with next year's revenue projected to grow by 29.00% to $217.1 million. Profitability remains a concern, as indicated by the negative EPS. The company's balance sheet strength is not detailed, but the significant revenue growth reported in the past suggests underlying business expansion. The current stock price of $8.73 is substantially below the median analyst price target of $19.00, indicating that the market may be undervaluing the company's long-term growth prospects.
Earnings & Growth Analysis
Regenxbio Inc. (RGNX) demonstrated a significant EPS beat in its most recent earnings report on August 6, 2026, reporting $0.43 against an estimate of -$0.11, a 490.91% surprise. Despite this strong beat, the stock price declined by 4.96%. Prior earnings reports show mixed performance, with a substantial miss in Q2 2026 (-$1.72 actual vs. -$1.41 estimate) and Q1 2026 (-$1.30 actual vs. -$0.84 estimate), but a beat in Q4 2025 ($1.87 actual vs. $1.61 estimate). This earnings history indicates earnings volatility, but the most recent positive surprise warrants attention.
Key Risks
Regenxbio Inc. (RGNX) faces significant risks, including its current technical weakness with the stock trading below key moving averages and a moderate insider sell signal, with total sales exceeding purchases by approximately $570,000. The company's negative EPS and volatile revenue growth also present fundamental challenges. Also, the recent stock price reaction to a significant EPS beat suggests that positive earnings news may not be translating into immediate stock appreciation, highlighting potential investor skepticism or broader market pressures.
Technical Indicators
| RSI (14) | 26.77 |
|---|---|
| MACD | -0.45 |
| SMA 50 | 10.86 |
| SMA 200 | 10.30 |
RSI
Oversold
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($10.86) above the 200-day SMA ($10.30), price is trading below the 50-day SMA, RSI at 26.8 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.31
Weak correlation
Nasdaq 100 (QQQ)
+0.30
Weak correlation
Bitcoin (BTC)
+0.05
Weak correlation
Gold (XAU)
+0.08
Weak correlation
Check Custom Correlation
Calculating correlation...
RGNX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🟢 LONG ENTRY (click to switch)
CONSERVATIVE
$8.374
2% below current price (Pullback entry)
Lower risk, wait for pullback
AGGRESSIVE
$8.545
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$7.498
MAX LOSS
-10.5%
Volatility-Adjusted Stop Loss
Calculated based on RSI (26.8) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$8.793
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$9.212
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$9.630
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
RGNX is classified as a high-volatility asset (Daily Vol: 6.34%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in RGNX in September 2016 would be worth about $6,443 today, compared with about $35,241 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RGNX today could grow to about $10,628 by 2036 in the base case, with a bull case near $80,633 and a bear case around $1,401. Projections are statistical simulations, not guarantees.
RGNX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $8.76 for RGNX by 2030 in the base case, from $8.55 today (1.0x over 4 years). The downside path ends near $2.43. These are outcomes of a Monte Carlo simulation run on RGNX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $4.53 | $8.60 | $16.32 |
| 2028 | $3.49 | $8.65 | $21.41 |
| 2029 | $2.87 | $8.70 | $26.40 |
| 2030 | $2.43 | $8.76 | $31.54 |
| 2031 | $2.10 | $8.81 | $36.92 |
| 2032 | $1.84 | $8.86 | $42.59 |
| 2033 | $1.64 | $8.92 | $48.59 |
| 2034 | $1.46 | $8.97 | $54.96 |
| 2035 | $1.32 | $9.03 | $61.72 |
| 2036 | $1.20 | $9.08 | $68.90 |
Method: 10,000 simulated price paths using RGNX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
RGNX Insider Trading Analysis
Bought
$949.4K
1 Transactions
Sold
$1.5M
8 Transactions
Insiders
15
Active Traders
Avg Transaction
$274.3K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 2, 2018 | VASISTA VITTAL
Chief Financial Officer
|
Sell | 73.4K | $5.2M |
| Dec 23, 2021 | FOX ALLAN MARK
Director
|
Sell | 112.9K | $3.9M |
| Oct 16, 2018 | SIMPSON CURRAN M
Officer
|
Sell | 62.3K | $3.8M |
| Feb 11, 2020 | SIMPSON CURRAN M
Chief Technology Officer
|
Sell | 57.0K | $2.9M |
| Feb 5, 2019 | SIMPSON CURRAN M
Chief Technology Officer
|
Sell | 43.8K | $2.2M |
| Sep 17, 2021 | FOX ALLAN MARK
Director
|
Sell | 48.2K | $2.2M |
| Nov 16, 2018 | SIMPSON CURRAN M
Officer
|
Sell | 32.9K | $2.1M |
| Nov 20, 2018 | BESHAR LUKE M
Director
|
Sell | 33.3K | $2.0M |
| Sep 14, 2021 | MILLS KENNETH THOMAS
Chief Executive Officer
|
Sell | 38.0K | $1.7M |
| Dec 11, 2020 | VASISTA VITTAL
Chief Financial Officer
|
Sell | 37.5K | $1.5M |
Page 1 of 1
Frequently Asked Questions
What is Regenxbio Inc.'s stock forecast for 2030?
Regenxbio Inc.'s stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $8.95, with a downside scenario of $2.48 and an upside scenario of $32.22. These figures are statistical outcomes, not guaranteed price targets.
Is Regenxbio Inc. stock a buy right now?
Regenxbio Inc. (RGNX) is currently rated a Buy with a consensus score of 77. The median analyst target price is $19.00, offering over 117% upside from the current price of $8.73, and the stock is in oversold territory technically.
What is Regenxbio Inc.'s current valuation?
Regenxbio Inc. has a negative P/E ratio due to its negative EPS of -$3.79. The current stock price of $8.73 is significantly below the median analyst price target of $19.00, suggesting it may be undervalued relative to analyst expectations.
How did Regenxbio Inc. perform in its latest earnings report?
In its latest earnings report on August 6, 2026, Regenxbio Inc. reported an EPS of $0.43, significantly beating the estimate of -$0.11 by 490.91%, although the stock price declined by 4.96%.
What are the key risks for Regenxbio Inc.?
Key risks for Regenxbio Inc. include its current technical weakness, a moderate insider sell signal, negative EPS, and volatile revenue growth. The stock's reaction to positive earnings also highlights potential investor skepticism.
What is Regenxbio Inc.'s revenue growth outlook?
While the current quarter's revenue is estimated to decline 44.00% year-over-year, Regenxbio Inc.'s outlook is positive for the next quarter and year, with projected revenue growth of 28.00% and 29.00% respectively.
Does Regenxbio Inc. pay a dividend?
Regenxbio Inc. does not currently pay a dividend, with a reported dividend yield and rate of 0%.